Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer
Status:
Withdrawn
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, topotecan, and estramustine, work
in different ways to stop tumor cells from dividing so they stop growing or die. Giving more
than one chemotherapy drug may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving paclitaxel, topotecan, and
estramustine together works in treating patients with metastatic hormone therapy-refractory
prostate cancer.